Important Deadline for Inovio Pharmaceuticals Investors Approaches in 2026 Securities Class Action

Inovio Pharmaceuticals Securities Class Action Alert

A recent reminder from the esteemed law firm Faruqi & Faruqi, LLP serves as a crucial alert for investors in Inovio Pharmaceuticals, Inc. (NASDAQ: INO). With the April 7, 2026 deadline looming, those who purchased or acquired Inovio securities between October 10, 2023, and December 26, 2025, should take urgent action. This alert underscores the significance of the impending deadline for filing as lead plaintiff in an ongoing federal securities class action against the company.

The Concerns Raised

Investors are advised to be aware of the allegations leveled against Inovio and its executives, which accuse them of violating federal securities laws. The complaint specifically highlights misleading statements and failures to disclose essential information regarding the company's CELLECTRA device's manufacturing deficiencies. Furthermore, it asserts that Inovio was unlikely to submit its Biologics License Application (BLA) for the INO-3107 treatment to the FDA in the anticipated timeframe, thereby heightening the risks surrounding its regulatory approvals and commercial prospects.

As recently as December 29, 2025, the U.S. Food and Drug Administration accepted Inovio’s BLA for the INO-3107 treatment, yet it cited that the information submitted was insufficient for accelerated approval. This discrepancy has led to a significant drop in Inovio's stock price, emphasizing the impact of regulatory uncertainties on investor confidence.

Call to Action for Investors

Faruqi & Faruqi encourages affected investors to reach out directly to Partner Josh Wilson to discuss available legal options. Investors should consider their potential eligibility as lead plaintiffs, overseeing and directing the litigation on behalf of their peers. Anyone holding relevant information about Inovio’s practices, including former employees and whistleblowers, is encouraged to come forward to assist in building the case.

The firm has established itself as a notable entity in securities law, recovering significant sums for investors since its inception in 1995. Ongoing updates can be followed through social media platforms including LinkedIn and X (formerly known as Twitter), or they can be contacted directly for further assistance.

Conclusion

Overall, this alert signifies a crucial moment for investors in Inovio Pharmaceuticals. With the deadline fast approaching, proactive steps are encouraged to safeguard financial interests and participate in the ongoing legal efforts against malpractices that may have caused financial harm. Maintaining awareness of the legal landscape surrounding Inovio is essential for investors looking to navigate these turbulent waters effectively.

For more information regarding the Inovio Pharmaceuticals class action, visit Faruqi & Faruqi’s dedicated webpage or contact them through the provided telephone numbers. This legal reminder underlines the importance of due diligence and timely action for affected investors.